Standard of Care: Initial & Maintenance Treatments

Managing Idiopathic Hypereosinophilic Syndrome (iHES) involves a two-part strategy: first, lowering your eosinophil count to suppress organ damage, and second, finding a long-term maintenance plan that keeps those levels stable while minimizing the side effects of treatment ^[1][2]. Because iHES is “idiopathic,” the focus is on controlling the immune response rather than targeting a specific genetic mutation ^[3].

Initial Treatment: Corticosteroids

Corticosteroids (often called “steroids”) remain the first-line treatment for almost all cases of iHES ^[1]. They work by rapidly reducing the production of eosinophils in your bone marrow and preventing them from migrating into your organs.

• Acute or Life-Threatening Cases: If you have severe organ damage, such as heart inflammation, specialists may use IV pulse therapy. In specialist protocols, this often involves high doses of methylprednisolone given through an IV to achieve a rapid reduction in eosinophil levels ^[2][4]. These are clinical examples, not self-treatment instructions.
• Routine Initial Care: For stable patients, treatment usually starts with oral prednisone or prednisolone ^[5][4].
• The Taper: Once your eosinophil count is under control, your doctor will slowly reduce (taper) the dose over several weeks or months. It is common for HES to “flare” or relapse during this taper, which is why a maintenance therapy is often added ^[6][7].

Crucial Safety Warnings for Corticosteroids:

• Never stop corticosteroids abruptly, as this can cause a life-threatening adrenal crisis.
• Strongyloides Risk: In a person with current or past exposure, corticosteroids can trigger fatal Strongyloides hyperinfection. Disclose your birthplace, travel, and soil exposure so clinicians can use serology, treatment, or empiric coverage (like ivermectin) when appropriate.
• Monitoring: Long-term steroids require diligent monitoring for high blood sugar, high blood pressure, bone thinning (osteoporosis), cataracts, mood changes, and serious infection risks.

Maintenance and “Steroid-Sparing” Therapy

The goal of maintenance therapy is to keep eosinophils low enough to protect your organs while allowing you to take the lowest possible dose of steroids ^[8].

Mepolizumab (Nucala)

Mepolizumab is an IL-5 antagonist, a biologic drug that blocks the specific signal (Interleukin-5) that eosinophils need to grow and survive ^[9].

• Dosing: For eligible patients with HES, the FDA-approved dose is 300 mg, given as three separate subcutaneous (under the skin) injections once every 4 weeks ^[9][10]. It is generally used as an add-on maintenance treatment rather than acute rescue for life-threatening organ injury.
• Effectiveness: In a major clinical trial, Mepolizumab reduced the proportion of patients experiencing an HES flare or study withdrawal by 50% versus placebo. It also allowed many patients to significantly reduce their daily steroid dose ^[10][8]. (Note: severe hypersensitivity and helminth infections must be discussed prior to use).

Second-Line and Refractory Options

If steroids or Mepolizumab are not enough to control the disease (steroid-refractory), your doctor may discuss older systemic treatments:

• Hydroxyurea: A chemotherapy pill that slows down the production of all blood cells. It has been used for decades to lower eosinophil counts in difficult cases, requiring frequent CBC and renal/hepatic monitoring ^[11][12].
• Interferon-alpha: An older injectable medication that can help regulate the immune system, though it carries significant psychiatric and autoimmune risks ^[1][13].

Other and Investigational Treatments

• Imatinib (Gleevec): While Imatinib is exquisitely effective when a PDGFRA or PDGFRB mutation is present, it is sometimes used off-label in refractory idiopathic HES by experienced specialists, as a subset of patients may still respond ^[1][14][4].
• Benralizumab (Fasenra): This is another biologic that targets the IL-5 receptor. While currently FDA-approved for asthma, it is being used off-label or in clinical trials for HES ^[15][16].
• Depemokimab: A new, long-acting IL-5 inhibitor being studied in clinical trials. It should not be presented as established care [NCT05334368].

Every patient’s response is unique. Your care team will use a combination of your symptoms, blood tests, and organ imaging (like heart scans) to fine-tune your treatment plan over time ^[17][18].